Patents by Inventor Kevin Rodzinak

Kevin Rodzinak has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Substituted quinolinones as PDE9 inhibitors
    Patent number: 10376504
    Abstract: The present invention is directed to azacyanoquinolinone compounds of the general structural formula: (wherein R5 and R6 are defined herein) which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: August 13, 2019
    Assignee: Merck, Sharp & Dohme Corp.
    Inventors: Antonella Converso, Kevin Rodzinak
  • Phenyl-cyanoquinolinone PDE9 inhibitors
    Patent number: 10370336
    Abstract: The present invention is directed to phenylcyanoquinolinone compounds which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: August 6, 2019
    Assignee: Merck Sharp & Dohme Corp.
    Inventors: Victoria Cofre, Antonella Converso, Kevin Rodzinak
  • Oxy-cyanoquinolinone PDE9 inhibitors
    Patent number: 10370337
    Abstract: The present invention is directed to oxycyanoquinolinone compounds which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Grant
    Filed: July 27, 2016
    Date of Patent: August 6, 2019
    Assignee: Merck, Sharp & Dohme Corp.
    Inventors: Antonella Converso, Mildred L. Kaufman, Kevin Rodzinak
  • OXY-CYANOQUINOLINONE PDE9 INHIBITORS
    Publication number: 20180258046
    Abstract: The present invention is directed to oxycyanoquinolinone compounds which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Application
    Filed: July 27, 2016
    Publication date: September 13, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: ANTONELLA CONVERSO, MILDRED L. KAUFMAN, KEVIN RODZINAK
  • AZA-CYANOQUINOLINONE PDE9 INHIBITORS
    Publication number: 20180214439
    Abstract: The present invention is directed to azacyanoquinolinone compounds which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Application
    Filed: July 27, 2016
    Publication date: August 2, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: ANTONELLA CONVERSO, KEVIN RODZINAK
  • PHENYL-CYANOQUINOLINONE PDE9 INHIBITORS
    Publication number: 20180208557
    Abstract: The present invention is directed to phenylcyanoquinolinone compounds which may be useful as therapeutic agents for the treatment of central nervous system disorders associated with phosphodiesterase 9 (PDE9). The present invention also relates to the use of such compounds for treating neurological and psychiatric disorders, such as schizophrenia, psychosis or Huntington's disease, and those associated with striatal hypofunction or basal ganglia dysfunction.
    Type: Application
    Filed: July 27, 2016
    Publication date: July 26, 2018
    Applicant: Merck Sharp & Dohme Corp.
    Inventors: VICTORIA COFRE, ANTONELLA CONVERSO, KEVIN RODZINAK
  • 1,3-Disubstituted Heteroaryl Nmda/Nr2b Antagonists
    Publication number: 20070293515
    Abstract: Compounds represented by Formula I: (wherein A, B, D, P, Q, R1, R2, R3, W and Y are described herein) or pharmaceutically acceptable salts thereof, are effective as NMDA/NR2B antagonists useful for treating neurological conditions such as, for example, pain, Parkinson's disease, Alzheimer's disease, epilepsy, depression, anxiety, ischemic brain injury including stroke, and other conditions.
    Type: Application
    Filed: July 29, 2005
    Publication date: December 20, 2007
    Inventors: Mark Layton, Kevin Rodzinak, Michael Kelly, Philip Sanderson